High Q Technologies and Creative Biostructure Partner to Deploy Quantum-Enabled EPR Spectroscopy

Why It Matters

The partnership gives pharma companies a practical route to probe intrinsically disordered targets, a class long considered undruggable, potentially accelerating pipeline timelines and expanding therapeutic options.

Key Takeaways

• High Q's FATHOM® integrates quantum sensor for EPR spectroscopy.
• Partnership offers pharma access to real‑time molecular motion data.
• Quantum sensor cuts sample volume to microgram levels.
• EPR data augments NMR and AI‑driven structural models.
• Simplifies EPR adoption for non‑specialist research teams.

Pulse Analysis

Quantum sensing is reshaping structural biology by overcoming the sensitivity limits of traditional spectroscopic tools. High Q Technologies’ FATHOM® platform replaces conventional microwave cavities with a cryogenic quantum sensor, enabling detection of magnetic‑field changes in protein samples as small as a few micrograms. This leap in sensitivity not only reduces reagent costs but also opens the door to studying transient conformations and aggregation pathways that are invisible to cryo‑EM or X‑ray crystallography. For drug developers, the ability to map long‑range distances in real time translates into clearer insights into how disordered proteins fold, interact, and respond to candidate molecules.

Creative Biostructure’s expertise in experimental design and data interpretation bridges the gap between raw quantum‑EPR output and actionable biological insight. By feeding FATHOM® distance constraints into NMR and machine‑learning‑driven structural pipelines, researchers can generate hybrid models that capture both static and dynamic aspects of biomolecular architecture. This integrated workflow shortens the iterative cycle of hypothesis, measurement, and model refinement, allowing teams to prioritize compounds with higher confidence before moving into costly preclinical studies. The partnership’s service model, which includes consultation and turnkey assay development, further democratizes access for laboratories lacking in‑house spectroscopy specialists.

The broader market implications are significant. As the pharmaceutical industry increasingly targets protein‑protein interactions and intrinsically disordered proteins—areas where conventional structural tools fall short—quantum‑enabled EPR offers a competitive advantage. Early adopters could achieve faster lead identification and de‑risk programs that previously required extensive trial‑and‑error. Moreover, the collaboration signals a growing convergence of quantum hardware with biotech services, hinting at a new wave of quantum‑driven drug‑discovery platforms that could reshape R&D investment strategies in the coming years.